Wearable EEG gadget aims to perfect seizure drug dosing at home
NCT ID NCT07225231
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a wearable device that records brain waves, heart rate, and movement at home can help doctors better adjust the dose of the seizure drug fenfluramine for people with Dravet syndrome or Lennox-Gastaut syndrome. Twenty patients will wear the device for 3-7 days at a time, three times total. Doctors will compare their confidence in dosing decisions with and without the home monitoring data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fenfluramine
- What this could lead to
- If successful, this could show that home EEG monitoring helps doctors fine-tune fenfluramine dosing more confidently for Dravet and Lennox-Gastaut patients.
- What could go wrong
- This is a very small early study (20 people) that only measures doctor confidence, not patient outcomes. It may not prove that home monitoring actually improves seizure control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME (DS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene therapy hopes to tame severe childhood epilepsy
- Smart brain pacemaker aims to stop seizures while you sleep
- New hope for babies with severe epilepsy: fenfluramine safety trial launches
- EEG clues may reveal who benefits from seizure drug
- Brain pacemaker trial aims to cut seizures in kids with severe epilepsy
- Study tests safer switch from street CBD to approved drug for kids with severe epilepsy